{"entity":{"id":"nct05588388","kind":"trial","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","aka":["BELIEVE"],"tldr":"A phase 2 trial of bevacizumab in lung cancer, run by Kamya Sankar, now recruiting.","summary":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases is a phase 2, interventional study registered as NCT05588388 by Kamya Sankar, with a registry enrolment figure of 39 participants, started 2024-08-11 and due to reach its primary completion in 2026-12-28. Interventions recorded: Bevacizumab. Conditions listed: Extensive-stage Small-cell Lung Cancer; Liver Metastases. Primary outcome: 6- month Progression Free Survival (PFS) rate. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group staging system), and radiographic confirmation of LM at diagnosis\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05588388","url":"https://clinicaltrials.gov/study/NCT05588388"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05588388","phase":"2","setting":"IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","sponsor":"Kamya Sankar","enrolled":39,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05588388/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}